Bepotastine besilate is a non-sedating, highly specific histamine-1 (H1) receptor antagonist and a potent mast cell stabilizer with inhibitory activity against eosinophil differentiation, activation, and migration, as well as several other inflammatory pathways. [1] [2] [3] [4] In animal models of allergic conjunctivitis, bepotastine besilate has been shown to be a more potent inhibitor of vascular hyperpermeability than olopatadine, ketotifen, or levocabastine. 
BEPREVE produced clinically significant reductions in ocular itch (greater than one unit improvement over baseline) in 95 % of all patient eyes at onset and in 90 % of all eyes at eight hours, following a single dose. 11 Furthermore, in patients whose ocular itching was graded severe (at least 3.0 on the standardized CAC 0-4 itch severity scale), 68 % of eyes had complete resolution of itch at three minutes post dose, compared with only 3 % of placebo-treated eyes. 12 Across these studies, BEPREVE was safe and well tolerated, with approximately 25 % of patients experiencing a mild, transient taste following instillation and 2-5 % of patients reporting eye irritation, headache, or nasopharyngitis. 13 Ocular comfort ratings for BEPREVE on instillation and five minutes post instillation were comparable to placebo. No dry mouth, dry eye, or drowsiness was reported by patients in the active arms. A comprehensive independent review of BEPREVE, including confirmation of its relative cost-effectiveness compared with other prescription (brand and generic) and over-the-counter ocular allergy products, was recently published.
under environmental exposure conditions are useful in expanding our picture of the clinical utility of this agent and establishing its place in our therapeutic armamentarium.
Duration of Action
While the efficacy results following allergen challenge at onset and eight hours supported the approval and bid dosing schedule of BEPREVE, the clinical study protocol also included efficacy evaluations following challenge at 16 hours from a single dose. In results published this year from the single-site trial, BEPREVE 1.5 % achieved statistically and clinically significant reductions in subject-assessed ocular itching, compared with placebo, at all time points (three, five, or seven minutes)
16 hours after dosing in the per-protocol population. 15 A significantly greater number of patients in the BEPREVE 1.5 % per-protocol population (p<0.001) and in the baseline severe itching subpopulation (p=0.005) achieved complete or near-complete elimination of itch at 16 hours compared with placebo.
Ocular Comfort
The ocular comfort of BEPREVE was established by the large safety trial, results of which have also been reported separately. 16 Figure 1 ) and therapeutic improvement in overall allergic condition at the end of the treatment period were also statistically superior for BEPREVE. BEPREVE was generally safe and well tolerated: the most frequently reported adverse events were bad/bitter taste (n=13; 10.6 %) and instillation site pain (n=3; 2.4 %). Table 1 ). In fact, two of the three studies in the Pataday data set failed to reach the 1.0 unit threshold, requiring a third study, in which the symptom check times were modified. Considering the available data, we can conclude that these agents appear to have similar durations of action, despite their different approved dosing schedules.
Based on the study by Spears et al., 17 BEPREVE and Pataday also appear to be very well tolerated on instillation, a benefit that may differentiate these agents from other prescription and over-the-counter agents.
Because patient adherence to therapy can be impacted by drop comfort, and our therapeutic goal is to alleviate ocular symptoms of allergy as quickly as possible, these differences in tolerability must be considered.
Lastly, we can now add a confirmatory, natural-exposure study to the clinical data set and investigator-initiated studies available to us in evaluating BEPREVE. Because it eliminates the inherent variability between subjects in environmental exposure studies, the validated, highly reproducible CAC study design has become the standard clinical protocol through which all ophthalmic antihistamine/mast cell stabilizers are approved. Interestingly, it is fundamentally a prophylaxis model, in that a subject with known sensitivity to an allergen is dosed with the study medication first and then challenged at specified time points.
Despite this, the FDA allows companies to request either a 'prevention' 
